Therefore, pharmacological approaches aiming to reduce the production of detrimental APP fragments and, at the same time, to increase the generation of non-amyloidogenic pathways peptides could be feasible strategies for the prevention and treatment of AD, and may also provide new guidance for TBI treatment. The gene discussed is APP; the disease is Alzheimer disease.